A rare case of inflammatory myopathy
DOI:
https://doi.org/10.18203/2349-3933.ijam20201067Keywords:
Corticosteroids, Inflammatory polymyositis, Type 2 diabetesAbstract
Idiopathic inflammatory myopathies (IIMs) happened to be the group of heterogeneous, systemic rheumatic diseases including adult polymyositis (PM), adult dermatomyositis (DM), myositis accompanied with another connective disease or cancer. A 52 years old male patient with known history of type 2 diabetes mellitus presented with complaints of muscle pain and swelling over left arm. These cases was successfully treated by using Corticosteroids. This cases study described the clinical presentation and features of inflammatory myositis. Although this is a rare case, its clinical features and treatment procedure helps in management of similar cases.
References
Hoogendijk JE, Amato AA, Lecky BR, Choy EH, Lundberg IE, Rose MR, et al. 119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10-12 October 2003, Naarden, The Netherlands. Neuromus Disorders. 2004 May 1;14(5):337-45.
Dalakas MC. Polymyositis, dermatomyositis, and inclusion-body myositis. N Engl J Med. 1991;325:1487-98.
Plotz PH, Dalakas M, Leff RL, Love LA, Miller FW, Cronin ME. Current concepts in the idiopathic inflammatory myopathies: polymyositis, dermatomyositis, and related disorders. Ann Intern Med. 1989;111:143-57.
Miller FW. Myositis-specific antibodies: touchstones for understanding the inflammatory myopathies. JAMA. 1993;270:1846-9.
Mastaglia FL, Ojeda VJ. Inflammatory myopathies: part 1. Ann Neurol. 1985;17:215-27.
Dalakas MC. Immunopathogenesis of inflammatory myopathies. Ann Neurol. 1995; 37:S74-S86.
Plotz PH, Rider LG, Targoff IN, Raben N, O’Hanlon TP, Miller FW. Myositis: immunologic contributions to understanding cause, pathogenesis, and therapy. Ann Intern Med. 1995;122:715-24.
Bohan A, Peter JB. Polymyositis and dermatomyositis. N Engl J Med. 1975;292:344-7.
Bohan A, Peter JB, Bowman RL, Pearson CM. A computer assisted analysis of 153 patients with polymyositis and dermatomyositis. Med. 1977;56:255-86.
Tymms KE, Webb J. Dermatopolymyositis and other connective tissue diseases: a review of 105 cases. J Rheumatol. 1985;12:1140-8.
De Vere R, Bradley WG. Poliomyositis: its presentation, morbidity and mortality. Brain. 1975;98:637-66.
Tanimoto K, Nakano K, Kano S, Mori S, Ueki H, Nishitani H, Sato T, Kiuchi T, Ohashi Y. Classification criteria for polymyositis and dermatomyositis. J Rheumatol. 1995;22(4):668-74.
Troyanov Y, Targoff IN, Tremblay JL, Goulet JR, Raymond Y, Senécal JL. Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and auto-antibodies: analysis of 100 French Canadian patients. Med. 2005;84(4):231-49.
Marie I, Hatron PY, Dominique S, Cherin P, Mouthon L, Menard JF, et al. Short-term and long-term outcome of anti-Jo1-positive patients with anti-Ro52 antibody. Semin Arthritis Rheum. 2012;41(6):890-9.
De Visser M, Emslie-Smith AM, Engel AG. Early ultrastructural alterations in adult dermatomyositis. Capillary abnormalities precede other structural changes in muscle. J Neurol Sci. 1989;94(1-3):181-92.
Emslie-Smith AM, Engel AG. Microvascular changes in early and advanced dermatomyositis: a quantitative study. Ann Neurol. 1990 Apr;27(4):343-56.
Dalakas MC, Illa I, Dambrosia JM, Soueidan SA, Stein DP, Otero C, et al. A controlled trial of high-dose intravenous immune globulin infusion as treatment for dermatomyositis. N Engl J Med. 1993;329:1993-2000.
Bolosiu HD, Man L, Rednic S. The effect of methylprednisolone pulse therapy in polymyositis/dermatomyositis. Adv Exp Med Biol. 1999;455:349-57.
Oddis CV, Reed AM, Aggarwal R, Rider LG, Ascherman DP, Levesque MC, et al. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum. 2013;65(2):314-24.
Muscle study group. A randomized, pilot trial of etanercept in dermatomyositis. Ann Neurol. 2011 Sep;70(3):427-36.
